Here are the 10-Q quarterly reports from Bristol-Myers Squibb $2PR (BMYMP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BMYMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMYMP filings page.
Bristol-Myers Squibb reported first-quarter 2026 total revenues of $11,489 million, up 3% from 2025, as strong demand in its Growth Portfolio and for Eliquis offset generic erosion in legacy cancer drugs and pricing pressure, especially in the U.S.
GAAP diluted EPS rose to $1.31 from $1.20, helped by lower amortization of acquired intangibles, while non-GAAP EPS fell to $1.58 from $1.80 mainly because diabetes royalty income ended in 2025. Operating cash flow was $1,104 million, and the company continues a restructuring plan targeting about $2.5 billion in charges and $2.0 billion in annual cost savings by 2027.
Bristol Myers Squibb (BMY) reported stronger Q3 2025 results. Total revenues were $12.222 billion versus $11.892 billion a year ago, and diluted EPS rose to $1.08 from $0.60. Net earnings attributable to BMS were $2.201 billion.
The Growth Portfolio generated $6.857 billion, led by Opdivo $2.532 billion, Orencia $964 million, Yervoy $739 million, and newer brands like Reblozyl $615 million, Breyanzi $359 million, Camzyos $296 million, and Opdualag $299 million. The Legacy Portfolio totaled $5.365 billion: Eliquis $3.746 billion grew, while Revlimid fell to $575 million and Pomalyst/Imnovid to $675 million.
Operating cash flow for the first nine months reached $12.182 billion, cash and equivalents increased to $15.726 billion, and long‑term debt was $44.469 billion. The company recorded Q3 Acquired IPRD of $633 million and highlighted strategic moves: a $1.5 billion upfront to BioNTech, a $350 million upfront to Philochem, and a $250 million milestone to SystImmune. BMS completed the 2seventy bio acquisition for $287 million and announced an agreement to acquire Orbital Therapeutics for $1.5 billion, subject to customary closing conditions. Restructuring charges are expected to total approximately $2.5 billion through 2027, with $1.6 billion incurred to date.